Cost of hospitalizing children with invasive pneumococcal pneumonia
Abstract
No abstract availableKeywords
Funding Information
- Instituto Salud Carlos III, Ministry of Heath, Madrid, Spain (PI10/02058)
This publication has 24 references indexed in Scilit:
- Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989–2008)Clinical Microbiology and Infection, 2011
- Healthcare utilization and cost of pneumococcal disease in the United StatesVaccine, 2011
- National Hospitalization Trends for Pediatric Pneumonia and Associated ComplicationsPediatrics, 2010
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009
- Emergence of Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes in the Era of 7-Valent Conjugate VaccineClinical Infectious Diseases, 2008
- Incidence of Pneumococcal Disease Due to Non–Pneumococcal Conjugate Vaccine (PCV7) Serotypes in the United States during the Era of Widespread PCV7 Vaccination, 1998–2004The Journal of Infectious Diseases, 2007
- Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysisThe Lancet, 2007
- Invasive Pneumococcal Disease Among Infants Before and After Introduction of Pneumococcal Conjugate VaccineJAMA, 2006
- Decrease of Invasive Pneumococcal Infections in Children Among 8 Children’s Hospitals in the United States After the Introduction of the 7-Valent Pneumococcal Conjugate VaccinePediatrics, 2004
- Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate VaccineNew England Journal of Medicine, 2003